What is Biofourmis?
Biofourmis is at the forefront of digital health innovation, leveraging artificial intelligence to analyze over 120 biomarkers in real-time. This capability allows for the identification of critical shifts in patient health, enabling proactive interventions and the delivery of hospital-level care directly to patients' homes. The company's platform facilitates connected access to virtual provider networks and life-changing clinical trials, all managed without the need for patients to leave their residences. This approach addresses the growing demand for accessible, efficient, and personalized healthcare solutions.
How much funding has Biofourmis raised?
Biofourmis has raised a total of $561.1M across 7 funding rounds:
Private Equity
$1M
Series A
$5M
Series B
$35M
Debt
$150K
Series C
$100M
Series D
$320M
Series C
$100M
Private Equity (2016): $1M with participation from SpesNet and Eden Strategy
Series A (2017): $5M led by NSI Ventures, Aviva, and The Northstar Group
Series B (2019): $35M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Series C (2020): $100M backed by Softbank Capital, Steamboat Ventures, EDBI, MassMutual Ventures, and Openspace Ventures
Series D (2022): $320M with participation from CVS Health, General Atlantic, and Trevor Fetter
Series C (2025): $100M led by Openspace Ventures, SoftBank Corp, Edbi, Massachusetts Mutual Life Insurance, and Sequoia Capital
Key Investors in Biofourmis
CVS Health
CVS Health is building a world of health around every consumer, aiming to deliver high-quality, affordable health care through unmatched reach and connected experiences. They are focused on improving health and well-being for those they serve.
General Atlantic
General Atlantic is a global growth-equity firm that provides capital and strategic support to high-growth companies in sectors including healthcare and technology, partnering with management teams to accelerate growth and international expansion.
Openspace Ventures
Openspace Capital is a multi-strategy asset manager specializing in Southeast Asia, focusing on tech-native and tech-enabled businesses across various stages of development, including early and growth-stage investments.
What's next for Biofourmis?
With its recent major strategic investment and substantial overall funding, Biofourmis is poised for accelerated growth and expansion. The company's focus on AI-driven remote care positions it to capitalize on the increasing adoption of telehealth and digital health solutions globally. Future strategic initiatives are likely to involve further development of its AI capabilities, expansion into new therapeutic areas, and strengthening partnerships with healthcare providers and payers. This sustained capital infusion will support Biofourmis in scaling its operations, enhancing its technological infrastructure, and solidifying its market leadership in the connected care ecosystem.
See full Biofourmis company page
